Skip to main content

HCW Biologics, Inc. (HCWB)

NASDAQ: HCWB · IEX Real-Time Price · USD
3.40 0.07 (2.10%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap121.21M
Revenue (ttm)4.10M
Net Income (ttm)-6.27M
Shares Out35.65M
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,179
Open3.36
Previous Close3.33
Day's Range3.33 - 3.55
52-Week Range3.26 - 7.78
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About HCWB

HCW Biologics is an innovative clinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. We believe age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. Our gateway indication is oncology. By the en...

IndustryBiotechnology
IPO DateJul 20, 2021
CEOHing C. Wong, Ph.D.
Employees40
Stock ExchangeNASDAQ
Ticker SymbolHCWB
Full Company Profile

Financial Performance

Financial Statements

News

4 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:FPAYHUSAPALI
3 weeks ago - Benzinga

5 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:AMPYBOXLREEDRSLS
4 weeks ago - Benzinga

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctiona...

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform

4 weeks ago - GlobeNewsWire

HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein ...

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells

1 month ago - GlobeNewsWire

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies t...

1 month ago - GlobeNewsWire

HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel i...

2 months ago - GlobeNewsWire

HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering

MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel i...

2 months ago - GlobeNewsWire

HCW Biologics IPO Registration Document (S-1)

HCW Biologics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC